Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Change in Acquisitions & Divestments (2022 - 2025)

Atara Biotherapeutics filings provide 4 years of Change in Acquisitions & Divestments readings, the most recent being $7.9 million for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments rose 127.5% to $7.9 million in Q4 2025 year-over-year; TTM through Mar 2026 was $7.9 million, a 74.47% decrease, with the full-year FY2025 number at $25.1 million, down 12.09% from a year prior.
  • Change in Acquisitions & Divestments hit $7.9 million in Q4 2025 for Atara Biotherapeutics, up from $1000.0 in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $89.2 million in Q1 2022 to a low of $1000.0 in Q3 2025.
  • Median Change in Acquisitions & Divestments over the past 4 years was $17.2 million (2025), compared with a mean of $37.0 million.
  • The widest YoY moves for Change in Acquisitions & Divestments: up 127.5% in 2025, down 99.97% in 2025.
  • Atara Biotherapeutics' Change in Acquisitions & Divestments stood at $50.7 million in 2022, then tumbled by 80.29% to $10.0 million in 2023, then tumbled by 65.3% to $3.5 million in 2024, then skyrocketed by 127.5% to $7.9 million in 2025.
  • The last three reported values for Change in Acquisitions & Divestments were $7.9 million (Q4 2025), $1000.0 (Q3 2025), and $17.2 million (Q1 2025) per Business Quant data.